gastrointestinal

Mahana raises $61m for digital therapeutic for IBS

Mahana Therapeutics has raised second-round financing of $61 million that will be used to launch what it says will be the first prescription digital therapeutics (DTx) for irritable bowel syndrome, one of several digital health products in its pipeline. The Mahana IBS tool – a three-month course that uses cognitive behavioural therapy (CBT) to log …

Mahana raises $61m for digital therapeutic for IBS Read More »

INVEST Pitch Perfect winner spotlight: Oshi builds digital approach for oft-overlooked GI conditions

As awareness grows around GI conditions, startup Oshi Health is building a platform to connect people to teams of clinicians and health coaches to better manage their symptoms. Judges picked the startup as the health services winner for MedCity INVEST’s Pitch Perfect contest. 

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested.  The decision – announced in the company’s first-quarter results statement – comes shortly after Lilly reported positive phase 3 results with mirikizumab in ulcerative colitis. The …

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions Read More »